Passage Bio, Inc. (NasdaqCM: PASG)
Health Care · Biotechnology · US
$3.50
-5.15% today · -59.0% 1Y
Passage Bio, Inc. (NasdaqCM: PASG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.26M and employs 24 people.
Over the last twelve months the share price has lost 59.0%, trading between 3.29 and 20.00.
Tweenvest scores Passage Bio, Inc. across four factors: quality 34/100, value 34/100. Its strongest factor is quality.
PASG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.26M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -11.31
- Dividend yield
- —
- Beta (5Y)
- 1.39
- 52-week high
- $20.00
- 52-week low
- $3.29
- Avg volume (3M)
- —
- Shares outstanding
- 3.22M
- Employees
- 24
- Next earnings
- —
About Passage Bio, Inc.
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
- ISIN
- US7027122099
- Founded
- 2017
- Listed since
- Feb 28, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pluri Inc.NasdaqCM: PLUR | $11.48M | $0.93 | -2.44% |
| Celyad Oncology SAENXTBR: CYAD | $11.43M | €0.23 | +13.50% |
| NGeneBio Co., Ltd.KOSDAQ: A354200 | $11.31M | ₩937.00 | +18.91% |
| Pharmigene, Inc.TPEX: 7595 | $11.28M | NT$7.25 | -2.03% |
| Patrys LimitedASX: PAB | $11.06M | AU$0.03 | -3.57% |
| IN8bio, Inc.NasdaqCM: INAB | $10.94M | $1.11 | -17.16% |
| Intensity Therapeutics, Inc.NasdaqCM: INTS | $10.94M | $3.35 | -7.71% |
| Cellectar Biosciences, Inc.NasdaqCM: CLRB | $10.78M | $1.14 | -21.38% |
Figures last refreshed Oct 18, 2026.